Xtandi: new oral androgen receptor inhibitor for metastatic prostate cancerDrug is intended for patients who have undergone medical or surgical castration and who have received docetaxel therapy. Prostate cancer: More men can opt for active surveillanceAll conventional criteria need not be fulfilled, analysis shows U.S. guideline nixes prostate screening in under-55s Late toxicities of cancer drugs Cardiac, pulmonary, sexual, and neurologic toxicities that develop or persist after completing cancer drug therapy Prostate cancer: More men can opt for active surveillance Not all conventional criteria need to be fulfilled, analysis shows New U.S. guideline nixes prostate cancer screening in under-55s Two-year interval suggested for older men who opt for testing Robot fails to impress in bladder cancer surgery High-tech approach no better than conventional open procedure Implants a cancer hazard New Drug: Perjeta for the treatment of HER2-positive metastatic breast cancer New drug is a recombinant, humanized, monoclonal antibody. Intermittent versus continuous prostate cancer therapy: New trial raises cautions in metastatic disease Researchers unable to conclude the two strategies produce equivalent results First Previous 40 41 42 43 44 Next Last
